Founded by three Investigators from Edison Biotechnology Institute (EBI) at Ohio University, Athens, OH, ASAKE Biotechnology, LLC is structured around research and development of novel health therapeutics utilizing natural resources. Specializing in biosynthetic technology and synthetic chemistry as well as emerging technologies including Proteolysis Targeting Chimeras (PROTAC) and living medicines, the firm's research efforts organize around infectious diseases, diabetes, and cancer. Focused on novel health therapeutics utilizing natural resources, principals of the firm specialize in biosynthetic technology and synthetic chemistry as well as emerging technologies. The latter includes Proteolysis Targeting Chimeras (PROTAC) and living medicines.
